



(19) Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 304 227 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: 03.03.93 (51) Int. Cl. 5: **A61L 15/16, A61K 9/70**

(21) Application number: **88307450.2**

(22) Date of filing: **11.08.88**

(54) **A method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a nonaqueous matrix.**

(30) Priority: **13.08.87 US 85052**

(43) Date of publication of application:
22.02.89 Bulletin 89/08

(45) Publication of the grant of the patent:
03.03.93 Bulletin 93/09

(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(56) References cited:
**US-A- 4 031 894
US-A- 4 230 105
US-A- 4 262 003
US-A- 4 532 244**

PATENT ABSTRACTS OF JAPAN, vol. 10, no. 296 (C-377)[2352], 8th October 1986; & JP-A-61 112 015 (NITTO ELECTRIC IND CO. LTD) 30-05-1986

(73) Proprietor: **ALZA CORPORATION
950 Page Mill Road P.O. Box 10950
Palo Alto California 94303-0802(US)**

(72) Inventor: **Campbell, Patricia S.
1410 Middlefield Road
Palo Alto California 94301(US)
Inventor: Enscore, David J.
18291 Montpere Way
Saratoga California 95070(US)
Inventor: Gale, Robert M.
1276 Russell Avenue
Los Altos California 94022(US)
Inventor: Kaufman, Arnold
637 Glenbrook Drive
Palo Alto California 94306(US)**

(74) Representative: **Evans, David Charles et al
F.J. CLEVELAND & COMPANY 40-43, Chancery Lane
London, WC2A 1JQ (GB)**

EP 0 304 227 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description**FIELD OF THE INVENTION**

This invention relates to the formation of liquid dispersions of a hydratable liquid in a nonaqueous matrix and more particularly relates to the manufacture of delivery devices which utilize such liquid dispersions in the delivery of drugs or other biologically active agents.

BACKGROUND OF THE INVENTION

Dispersions of drugs or other biological agents in nonaqueous, typically polymeric, matrices are commonly used as reservoirs for delivery devices, representative devices being disclosed U.S. patents 3,598,122 and 3,598,123 to Zaffaroni et al, 4,031,894 to Urquhart et al and 4,201,211 to Chandrasekaran et al which patents are incorporated herein by reference. For convenience the term "drug" will be hereafter used in its broadest sense to include any biologically active agent which is delivered to its environment of use to produce a biological effect. The drugs may be in solid form as for example in Chandrasekaran et al or in the form of a liquid dispersion as in Urquhart et al. It is with respect to such liquid dispersions that this invention relates.

Although this invention will be described hereafter specifically with respect to scopolamine delivery devices, it should be recognized that it is applicable to dispersions of any other drug which is in a liquid state at ambient temperatures and forms a crystalline hydrate upon exposure to water. Such drugs as nicotine, secoverine and benzotropine, for example, may, to the extent they form crystalline hydrates, be treated in a manner similar to the methods by which dispersions of scopolamine base are treated according to this invention.

Transdermal delivery devices for the administration of scopolamine of the type disclosed by Urquhart et al are used extensively for the prevention of motion sickness. The product is manufactured as described in the patent by solvent casting of chloroform solutions of scopolamine base in polyisobutylene (PIB) and mineral oil (MO) onto impermeable webs to form drug reservoir and adhesive films. Upon evaporation of the chloroform, a dispersion of liquid scopolamine base in the PIB/MO matrix is formed. The drug reservoir and adhesive films are then laminated to opposite sides of a release rate controlling membrane, formed from a mineral oil impregnated microporous film, to produce a multilaminate comprising a removable release liner lamina, an adhesive lamina, a rate controlling membrane lamina, a drug reservoir lamina and an impermeable backing lamina. The

multilaminate is then die cut into individual systems and packaged in individual heat sealed foil pouches.

The manufacture of the product in this manner was carried out for approximately five years with no indication of the formation of any crystals of scopolamine hydrate in either the drug reservoir or the adhesive. After that time, small crystals of scopolamine hydrate were observed, but this did not present a problem because the release rate of the drug from the device was not affected by the presence of the small number of small crystals then occurring.

Approximately two years later, larger numbers of rapidly propagating crystals were observed, primarily in the drug reservoir, with a lower incidence being observed in the contact adhesive layer which contained a lower concentration of scopolamine base. At that time, the size of the crystals and their frequency of occurrence had increased to the point where they produced a significant adverse effect on the release rate of scopolamine from the device. Thereafter, every lot manufactured developed unacceptably high crystal size and frequency and commercial production had to be halted until the problem could be solved.

The individual laminate films and the multilaminate films exhibited crystallization at a much lower frequency. After the multilaminate film was fed through the die-cutting machine for the formation of the individual transdermal delivery units, crystallization began around the edges of the cut product and crystalline growth thereafter propagated rapidly throughout the mass of the reservoir and in some cases the adhesive layer. Visually observable crystals were not necessarily apparent immediately after the cutting step; instead they would typically develop over a period of days. Microscopic examination detected crystals at an earlier stage, suggesting that submicroscopic nucleation sites are present at an even earlier time.

It should be noted that the above described crystallization phenomena occurred without any significant change in the manufacturing facilities, equipment or processes and, once it had occurred, if never ceased occurring. Various attempts to eliminate the problem were tried over several months, all to no avail. For example, the drug reservoir laminate, adhesive laminate and the multilaminate film were heated overnight with no observable effect. The casting solutions were similarly heated and allowed to stand for extended periods also with no effect. Because crystallization seemed to appear after the step in which the multilaminate film is cut into individual devices, cutting and packaging the systems under dry nitrogen was instituted but crystals still appeared.

Attempts were also made to remove water from other stages of the manufacturing process. The scopolamine base is produced from an aqueous solution of scopolamine hydrobromide by titration to a basic pH with sodium hydroxide and extracting the base so formed with chloroform. The chloroform solution of the scopolamine base is then admixed with the PIB and MO as described in the aforesaid Urquhart et al patent to provide the appropriate casting solutions.

To reduce the amount of residual water in the chloroform solution of the scopolamine base, the solution was dried with drying agents such as anhydrous sodium sulfate and magnesium sulfate. Crystallization still occurred. The chloroform solution was exposed to a molecular sieve material in order to remove residual water. Crystallization still occurred. Azeotropic distillation of the chloroform solution was attempted, again to no avail even though the water content was significantly reduced.

Another approach considered was to allow the casting solutions to age for up to two weeks prior to casting and to heat the solutions prior to casting up to 60°C overnight. This too was ineffective in preventing the occurrence of the crystals.

Against this background, it was therefore totally unexpected when the process developed by the applicants was tested and found successful for the prevention of the formation of the scopolamine hydrate crystals.

It is accordingly an object of this invention to prevent the formation of crystalline hydrate in a dispersion of a hydratable liquid in a nonaqueous matrix.

It is another object of this invention to prevent formation of crystals of scopolamine hydrate in dispersions of scopolamine base in a nonaqueous matrix.

It is another object of this invention to manufacture transdermal therapeutic systems for the controlled delivery of scopolamine base which are free from crystals of scopolamine hydrate.

According therefore to the present invention there is provided a process for producing a laminated structure within a sealed container which comprises:

- a. forming a laminated structure, at least one lamina of which comprises a dispersion of a liquid capable of forming a crystalline hydrate in a nonaqueous matrix; and
- b. packaging said subunits in a sealed container; characterised by
- c. heating said laminated structure in said sealed container to a temperature at or above the melting point of the crystalline hydrate;
- d. maintaining said structure at said temperature for a period of time sufficient to prevent formation of said crystalline hydrate for a substantial

period of time after cooling of said laminated structure to ambient temperatures; and

e. cooling said laminated structure in said sealed container to ambient temperatures, whereby crystallization of said hydratable liquid is substantially prevented.

These and other objects of this invention will be readily apparent from the following description of the invention.

DESCRIPTION OF THE INVENTION

According to our invention, we have found that the formation of crystalline hydrates in a liquid dispersion of a hydratable liquid in a nonaqueous, typically polymeric, matrix can be prevented if, after the articles to be manufactured from the dispersion have been cut to shape and preferably after they have been placed in their packages, the articles are heated to a temperature above the melting point of the crystalline hydrate, are maintained at that temperature for a period of time and then allowed to cool to ambient conditions. We have found that when so treated, crystals initially present disappear, do not reform upon cooling to ambient conditions and have not shown signs of crystal formation after storage at ambient conditions and under accelerated aging conditions for several months.

The temperature and time are not critical provided they are adequate to prevent the formation of crystals after cooling and are not so high as to cause damage to either the containers or the contents thereof. If crystals are initially present, the temperature must be at, and preferably above, the melting point of the hydrate and the time should be sufficient to cause melting of all the crystals present. It is preferable from the point of quality assurance and uniformity of processing conditions to heat above the melting point. We have found that, with respect to preventing the formation of crystals of the hydrate of scopolamine base having a melting point of 59°C., heating the units to 60°C. for 24 hours was sufficient to melt the crystals that were present and to prevent the formation of crystals after cooling. It is contemplated, however, that a lower temperature and a shorter time could still be effective according to this invention. Suitable temperatures and times for any particular system can be readily determined by workers skilled in the art.

Although this invention will be described with respect to a specific example relating to the manufacture of transdermal delivery devices for the controlled delivery of scopolamine, it should be recognized that this invention is applicable to the processing of dispersions of any liquid agent capable of forming a crystalline hydrate. Liquid agents

which may have these characteristics include, without limitation, secoverine, benztrapine and nicotine.

Having thus generally described our invention, the following specific example is provided.

EXAMPLE I

Scopolamine base was formed by dissolving scopolamine hydrobromide in an aqueous sodium bicarbonate sodium carbonate buffer solution. Sodium hydroxide was added until a pH of about 9.6 was reached at which point the scopolamine base precipitated from solution and was extracted with chloroform. The chloroform solution of scopolamine base was then used as the source of scopolamine in the following preparation. 20.9 parts high molecular weight PIB (sold under the designation Vistanex L-100, 1,200,000 viscosity average molecular weight), 26.1 parts low molecular weight PIB (sold under the designation Vistanex LM-MS, 35,000 viscosity average molecular weight), 41.7 parts mineral oil (10 cp at 25°C) and 11.3 parts scopolamine base were dissolved in chloroform in a mixer and solvent cast to form a film approximately 50 micrometers dry thickness on an approximately 65 micrometer backing film of aluminized polyethylene terephthalate (sold under the designation Scotchpak®) to form, upon evaporation of the chloroform, a scopolamine base reservoir-impermeable backing laminate. The contact adhesive layer/strippable release liner laminate was similarly prepared by solvent casting onto a 75 micrometer siliconized, polyethylene terephthalate film, a 50 micrometer dry thickness adhesive layer formed from a chloroform solution of 23.1 parts of said high molecular weight polyisobutene, 28.8 parts of said low molecular weight polyisobutene, 46.1 parts of said mineral oil, and 2.0 parts of said scopolamine base. The backing-reservoir laminate and the adhesive-release liner laminate were then laminated to opposite sides of a 25 micrometer microporous polypropylene membrane (sold under the designation Celgard® 2400) saturated with mineral oil and 2.5 cm² circular disk-shaped bandages were punch-cut from the resulting five-layer laminate. The individual bandages so produced were packaged within heat-sealed foil-lined pouches. The pouches were then heated in an oven to 60°C. and held at that temperature for 24 hours and thereafter allowed to cool to ambient conditions.

Samples treated according to this invention and samples manufactured as described above without the final heating step have been monitored over periods of up to 6 months and other have been monitored over periods of up to 6 months and other samples have been subjected to accelerated aging at 37°C for like periods. To date, none of the samples treated according to this invention

exhibited any crystallization, whereas the control samples not subjected to the final heating step ultimately developed scopolamine hydrate crystals which unacceptably affected the release rate. The devices produced according to this invention, however, exhibited release rates within the applicable specifications for the product. Further, the accelerated aging studies indicate that the product produced according to this invention should remain stable for at least 3 years, a typical shelf life for a product of this type.

The above described Example contained dispersions of the drug in both the reservoir and adhesive laminae because the device contained a priming dose of the drug in the adhesive. It should be recognized however that the adhesive lamina need not contain a priming dose in which case only the reservoir lamina would be a dispersion of the liquid drug, the adhesive lamina comprising a solution of the drug in the polymer matrix.

Claims

1. A process for producing a laminated structure within a sealed container which comprises:

- a. forming a laminated structure, at least one lamina of which comprises a dispersion of a liquid capable of forming a crystalline hydrate in a nonaqueous matrix; and
- b. packaging said subunits in a sealed container;

characterised by

- c. heating said laminated structure in said sealed container to a temperature at or above the melting point of the crystalline hydrate;

- d. maintaining said structure at said temperature for a period of time sufficient to prevent formation of said crystalline hydrate for a substantial period of time after cooling of said laminated structure to ambient temperatures; and

- e. cooling said laminated structure in said sealed container to ambient temperatures, whereby crystallization of said hydratable liquid is substantially prevented.

2. The process of claim 1 wherein said temperature is above the melting point of said crystalline hydrate.

3. The process of claim 1 or 2 in which said liquid capable of forming a crystalline hydrate is selected from scopolamine, secoverine, benztrapine and nicotine.

4. A process for producing a laminated dosage form of scopolamine packaged within a sealed

container which comprises:

- a. forming a laminated dosage form of of scopolamine, at least one lamina of which comprises a dispersion of a liquid scopolamine base in a nonaqueous matrix; and
- b. packaging said dosage form in a sealed container; characterised by
- c. heating said dosage form in said sealed container to a temperature at or above the melting point of the crystalline hydrate;
- d. maintaining said dosage form at said temperature for a period of time sufficient to prevent formation of a crystalline of scopolamine base for a substantial period of time after cooling of said dosage form to ambient temperatures; and
- e. cooling said dosage form in said sealed container to ambient temperatures.

5. The process of claim 4 wherein said temperature is at least about 60 °C.

6. The process of claim 1, 2, 3, 4 or 5 wherein said time is about 24 hours.

Patentansprüche

1. Verfahren zur Herstellung einer laminierten Struktur in einem versiegelten Behälter, wobei das Verfahren folgende Schritte umfaßt:

- (a) Bilden einer laminierten Struktur, in der wenigstens eine dünne Schicht eine Dispersion einer Flüssigkeit umfaßt, die ein kristallines Hydrat in einer nicht wässrigen Matrix bilden kann; und
- (b) Verpacken der Untereinheiten in einen versiegelten Behälter;

dadurch gekennzeichnet, daß man

- (c) die laminierte Struktur in dem versiegelten Behälter auf eine Temperatur beim Siedepunkt oder oberhalb des Siedepunkts des kristallinen Hydrats erhitzt;
- (d) die Struktur bei der Temperatur für eine Zeitspanne hält, die ausreichend ist, um die Bildung des kristallinen Hydrats für eine wesentliche Zeitspanne nach dem Abkühlen der laminierten Struktur auf Umgebungstemperaturen zu verhindern; und
- (e) die laminierte Struktur in dem versiegelten Behälter auf Umgebungstemperaturen abkühlt, wobei eine Kristallisation der hydratisierbaren Flüssigkeit im wesentlichen verhindert wird.

2. Verfahren nach Anspruch 1, worin die Temperatur oberhalb des Schmelzpunkts des kristallinen Hydrats liegt.

3. Verfahren nach Anspruch 1 oder Anspruch 2, worin die Flüssigkeit, die ein kristallines Hydrat bilden kann, gewählt ist unter Scopolamin, Secobarbin, Benztrapin und Nikotin.

4. Verfahren zur Herstellung einer laminierten Scopolamin-Dosierungsform, die in einem versiegelten Behälter verpackt ist, wobei das Verfahren folgende Schritte umfaßt:

- (a) Bilden einer laminierten Scopolamin-Dosierungsform, in der wenigstens eine Schicht eine Dispersion einer flüssigen Scopolamin-Base in einer nicht wässrigen Matrix umfaßt; und
 - (b) Verpacken der Dosierungsform in einem versiegelten Behälter;
- dadurch gekennzeichnet, daß man
- (c) die Dosierungsform in dem versiegelten Behälter auf eine Temperatur beim Schmelzpunkt oder oberhalb des Schmelzpunkts des kristallinen Hydrats erhitzt.
 - (d) die Dosierungsform bei der Temperatur für eine Zeitspanne hält, die ausreichend ist, die Bildung einer kristallinen Scopolamin-Base für eine wesentliche Zeitspanne nach dem Abkühlen der Dosierungsform auf Umgebungstemperaturen zu verhindern; und
 - (e) die Dosierungsform in dem versiegelten Behälter auf Umgebungstemperaturen abkühlt.

5. Verfahren nach Anspruch 4, worin die Temperatur wenigstens etwa 60 °C beträgt.

6. Verfahren nach Anspruch 1, Anspruch 2, Anspruch 3, Anspruch 4 oder Anspruch 5, worin die Zeit etwa 24 Stunden beträgt.

Revendications

1. Procédé de préparation d'une structure stratifiée dans un récipient fermé, comprenant:

- a. la formation d'une structure stratifiée, dont au moins une couche comprend une dispersion d'un liquide capable de former un hydrate cristallin dans une matrice non aquueuse; et
- b. le conditionnement desdites sous-unités dans un récipient fermé, caractérisé en ce que:
- c. on chauffe ladite structure stratifiée dans ledit récipient fermé à une température égale ou supérieure au point de fusion de l'hydrate cristallin;

d. on maintient ladite structure à ladite température pendant une durée suffisante pour empêcher la formation dudit hydrate cristallin pendant une durée substantielle après le

- refroidissement de ladite structure stratifiée aux températures ambiantes; et
e. on refroidit ladite structure stratifiée dans ledit récipient fermé aux températures ambiantes, ce qui empêche dans une mesure substantielle la cristallisation dudit liquide hydratable.
- 5
2. Procédé selon la revendication 1, caractérisé en ce que ladite température est supérieure au point de fusion dudit hydrate cristallin. 10
3. Procédé selon la revendication 1 ou 2, caractérisé en ce que ledit liquide capable de former un hydrate cristallin est choisi parmi la scopolamine, la secovérine, la benztrapine et la nicotine. 15
4. Procédé de préparation d'une forme posologique stratifiée de scopolamine conditionnée dans un récipient fermé, dans lequel:
a. on forme une forme posologique stratifiée de scopolamine, dont au moins une couche comprend une dispersion d'un liquide à base de scopolamine dans une matrice non aqueuse; et
b. on conditionne ladite forme posologique dans un récipient fermé, caractérisé en ce que
c. on chauffe ladite forme posologique dans ledit récipient fermé à une température égale ou supérieure au point de fusion de l'hydrate cristallin;
d. on maintient ladite forme posologique à ladite température pendant une durée suffisante pour empêcher la formation d'une forme cristalline à base de scopolamine pendant une durée substantielle après le refroidissement de ladite forme posologique aux températures ambiantes; et
e. on refroidit ladite forme posologique dans ledit récipient fermé aux températures ambiantes.
- 20
- 25
- c. on chauffe ladite forme posologique dans ledit récipient fermé à une température égale ou supérieure au point de fusion de l'hydrate cristallin;
- d. on maintient ladite forme posologique à ladite température pendant une durée suffisante pour empêcher la formation d'une forme cristalline à base de scopolamine pendant une durée substantielle après le refroidissement de ladite forme posologique aux températures ambiantes; et
- e. on refroidit ladite forme posologique dans ledit récipient fermé aux températures ambiantes.
- 30
- 35
5. Procédé selon la revendication 4, caractérisé en ce que ladite température est d'au moins environ 60 °C. 45
6. Procédé selon l'une quelconque des revendications 1, 2, 3, 4 et 5, caractérisé en ce que ladite durée est d'environ 24 heures. 50